Clinical Trial Update: Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating abemaciclib for molecular residual disease detected by circulating tumor DNA in HR-positive/HER2-negative early breast cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Nagoya City University | Conditions: ctDNA Monitoring, Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING